News & Updates
Filter by Specialty:
T2D risk elevated in thyroid cancer patients after thyroidectomy
Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.
T2D risk elevated in thyroid cancer patients after thyroidectomy
05 Mar 2022
Corticosteroids up incidence of adverse events, readmissions in severe COPD
A single-institution study does not recommend the prescription of systemic corticosteroids for the treatment of severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as this might result in an increased incidence of adverse effects and readmissions.
Corticosteroids up incidence of adverse events, readmissions in severe COPD
05 Mar 2022
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
A real-world propensity score-matched study in Hong Kong finds that, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors, use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes (T2D) patients is associated with lower risk of incident atrial fibrillation (AF), stroke/transient ischaemic attack (TIA), and cardiovascular (CV) and all-cause mortality.
T2D: Risk of CV and all-cause mortality lower with SGLT2 vs DPP-4 inhibitors
05 Mar 2022
Physically active women less reliant on pain meds for headache
A cross-sectional study by the German Migraine and Headache Society reports a lower use of analgesics among physically active women prone to headaches vs physically inactive counterparts.
Physically active women less reliant on pain meds for headache
05 Mar 2022
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
04 Mar 2022
Empiric antibiotic use confers no therapeutic benefit in COVID-19 pneumonia
The use of empiric antibiotic therapy appears to prevent neither deterioration nor death among patients with COVID-19 pneumonia, as shown in a Singapore study.
Empiric antibiotic use confers no therapeutic benefit in COVID-19 pneumonia
04 Mar 2022
Ustekinumab safe, effective in Asians with severe plaque psoriasis
Ustekinumab, a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, demonstrates effectiveness and safety in the treatment of multiethnic Asian patients with moderate to severe plaque psoriasis, according to a Singapore study.